Biomarkers for immuno-oncology: tumour mutational load and beyond. The impact of a multidimensional approach Philip Jermann, PhD Head of Molecular Assay Development Unit Institute of Medical Genetics and Pathology University Hospital Basel, Switzerland
20
Embed
Biomarkers for immuno-oncology: tumour mutational load and ......Biomarkers for immuno-oncology: tumour mutational load and beyond. The impact of a multidimensional approach Philip
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Biomarkers for immuno-oncology: tumourmutational load and beyond.
The impact of a multidimensional approachPhilip Jermann, PhD
Head of Molecular Assay Development UnitInstitute of Medical Genetics and Pathology
University Hospital Basel, Switzerland
Understanding Tumor-Immune Interactions Through NGSUsing genomic assays to improve the success of immunotherapy
Tumor-Immune interactions are complex
and warrants a multi-marker approach
NGS assays broaden our understanding of the
biology beyond traditional IHC biomarkers
PD-L1
IHC
Source: Thermo Fisher Scientific
Understanding Tumor-Immune Interactions Through NGSUsing genomic assays to improve the success of immunotherapy
Tumor-Immune interactions are complex
and warrants a multi-marker approach
NGS assays broaden our understanding of the
biology beyond traditional IHC biomarkers
PD-L1
IHC
Source: Thermo Fisher Scientific
Tumor mutational burden (TMB)An assessment of the number of somatic mutations within a tumor genome
High somatic mutation load Higher neoantigen load Greater response to immunotherapy
Recognition of
neoantigens by T cells
More likely to
form neoantigens
Mutational landscape determines sensitivity to
PD-1 blockade in non-small cell lung cancer1
Genetic basis for clinical response to
CTLA-4 blockade in melanoma2
Genomic correlation of response to CTLA-4
blockade in metastatic melanoma3
Ove
rall
su
rviv
al
0 500 1000 1500
Nivolumab plus Ipilimumab in Lung Cancer
with a High Tumor Mutational Burden
(Checkmate 227)5
Whole exome sequencing studies:
Tumor mutational burden (TMB) as a
biomarker for clinical benefit from dual immune
checkpoint … (Checkmate 568)4
Targeted NGS studies:
1Rizvi et al. Science (2015); 2Snyder et al. N Eng J Med (2014); 3Van Allen at al. Science (2015); 4Ramalingam et al. AACR 2018; 5Hellman et al. N Eng J Med (2018); Neoantigen artwork credit: Dr. Bjoern Peters
High TMB has been found to correlate with response to immune checkpoint inhibitor treatment
Retrospective analysis of NSCLC samples treated with ICIs
Retrospective study to evaluate TMB as a potential biomarker for ICI treatment
The data presented here represent a sole property of the author and his institution. Thermo Fisher Scientific and its affiliates are not endorsing, recommending, or promoting any use or
application of Thermo Fisher Scientific products presented by third parties during this seminar. Information and materials presented or provided by third parties are provided as-is and
without warranty of any kind, including regarding intellectual property rights and reported results. Parties presenting images, text and material represent they have the rights to do so.
Speaker was provided travel support by Thermo Fisher Scientific for this presentation, but no remuneration.